These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26196746)

  • 1. Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK.
    Nakano T; Saiki Y; Kudo C; Hirayama A; Mizuguchi Y; Fujiwara S; Soga T; Sunamura M; Matsumura N; Motoi F; Unno M; Horii A
    Biochem Biophys Res Commun; 2015 Sep; 464(4):1084-1089. PubMed ID: 26196746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
    Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
    Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
    Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
    Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
    Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
    Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
    Patel GK; Khan MA; Bhardwaj A; Srivastava SK; Zubair H; Patton MC; Singh S; Khushman M; Singh AP
    Br J Cancer; 2017 Feb; 116(5):609-619. PubMed ID: 28152544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
    Funamizu N; Okamoto A; Kamata Y; Misawa T; Uwagawa T; Gocho T; Yanaga K; Manome Y
    Oncol Rep; 2010 Feb; 23(2):471-5. PubMed ID: 20043109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
    Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.
    Galmarini CM; Clarke ML; Jordheim L; Santos CL; Cros E; Mackey JR; Dumontet C
    BMC Pharmacol; 2004 May; 4():8. PubMed ID: 15157282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
    Jordheim LP; Galmarini CM; Dumontet C
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):547-54. PubMed ID: 16463058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
    Kerr M; Scott HE; Groselj B; Stratford MR; Karaszi K; Sharma NL; Kiltie AE
    Clin Cancer Res; 2014 Nov; 20(21):5435-45. PubMed ID: 25224279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
    Dash S; Ueda T; Komuro A; Amano H; Honda M; Kawazu M; Okada H
    Mol Cancer Res; 2023 May; 21(5):444-457. PubMed ID: 36757299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
    Hodzic J; Giovannetti E; Diosdado B; Adema AD; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1214-22. PubMed ID: 22132977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
    Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
    Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer.
    Dash S; Ueda T; Komuro A; Honda M; Sugisawa R; Okada H
    Cell Death Dis; 2024 Feb; 15(2):131. PubMed ID: 38346958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.
    Vernejoul F; Ghénassia L; Souque A; Lulka H; Drocourt D; Cordelier P; Pradayrol L; Pyronnet S; Buscail L; Tiraby G
    Mol Ther; 2006 Dec; 14(6):758-67. PubMed ID: 17000136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.